Nivimedore(BRL10833,化学名2-硝基-5,6-二甲基茚满-1,3-二酮,下简称Ⅰ)是一种新的口服有效的抗哮喘药,服用形式为其钠盐的一水化物。该药有三个电还原基团,即两个羰基和一个硝基。其还原作用取决于pH。在酸性介质中由四个电子还原硝基所产生的极谱波具有很高的选择性和精密度。用于胶囊中药物分析时,其相对标准偏差为1.3%,在置信度95%时为±2.6%和相当于±0.15mg/每胶囊。本法亦适用于原料或片制中(包括稳定性)药物的检测。用100ml Britton-Robinson(BR)缓冲液(pH1.81～11.98)稀释1mlⅠ的钠盐(一水化物)储备液(浓度为2×10~(-3)M)以获得pH范围为3～11的一系列溶液。用氮除去试液中的氧,并用直流极谱法和差示脉 Nivimedore (BRL10833, chemical name 2-nitro-5,6-dimethylindane-1,3-dione, hereinafter referred to as I) is a new orally active antiasthmatic agent in the form of its sodium salt A hydrate. The drug has three electroreduction groups, two carbonyls and one nitro group. Its reduction depends on pH. The polarographic wave produced by the reduction of the nitro group by four electrons in an acidic medium has a high degree of selectivity and precision. The relative standard deviation was 1.3% for drug analysis in capsules, ± 2.6% for 95% confidence and ± 0.15 mg / capsule. This Law also applies to the testing of pharmaceuticals (including stability) in raw materials or tablets. 1 ml of a sodium salt (monohydrate) stock solution of I (2 x 10 -3 M) was diluted with 100 ml of Britton-Robinson (BR) buffer (pH 1.81 to 11.98) to obtain a pH range of 3 to 11 A series of solutions. Nitrogen in the test solution was removed with nitrogen and analyzed by direct current polarography and differential pulse